DE3650620T2 - Behandlungsverfahren kataboler dysfunktion - Google Patents

Behandlungsverfahren kataboler dysfunktion

Info

Publication number
DE3650620T2
DE3650620T2 DE3650620T DE3650620T DE3650620T2 DE 3650620 T2 DE3650620 T2 DE 3650620T2 DE 3650620 T DE3650620 T DE 3650620T DE 3650620 T DE3650620 T DE 3650620T DE 3650620 T2 DE3650620 T2 DE 3650620T2
Authority
DE
Germany
Prior art keywords
treatment method
catabolic dysfunction
catabolic
dysfunction
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3650620T
Other languages
English (en)
Other versions
DE3650620D1 (de
Inventor
Douglas Wilmore
Robert Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25103680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3650620(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of DE3650620D1 publication Critical patent/DE3650620D1/de
Application granted granted Critical
Publication of DE3650620T2 publication Critical patent/DE3650620T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE3650620T 1985-09-12 1986-09-12 Behandlungsverfahren kataboler dysfunktion Expired - Lifetime DE3650620T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77521485A 1985-09-12 1985-09-12
PCT/US1986/001870 WO1987001589A1 (en) 1985-09-12 1986-09-12 Method of treating catabolic dysfunction

Publications (2)

Publication Number Publication Date
DE3650620D1 DE3650620D1 (de) 1997-06-12
DE3650620T2 true DE3650620T2 (de) 1997-09-11

Family

ID=25103680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3650620T Expired - Lifetime DE3650620T2 (de) 1985-09-12 1986-09-12 Behandlungsverfahren kataboler dysfunktion

Country Status (8)

Country Link
EP (1) EP0238553B1 (de)
JP (1) JPH0794389B2 (de)
AT (1) ATE152621T1 (de)
AU (1) AU599335B2 (de)
CA (1) CA1285491C (de)
DE (1) DE3650620T2 (de)
DK (1) DK175711B1 (de)
WO (1) WO1987001589A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310768A (en) * 1987-10-29 1994-05-10 Ab Erik Vinnars Method for improving the glutamine content in skeletal muscle and composition therefore
IL94549A (en) * 1989-06-02 1996-08-04 Brigham & Womens Hospital A pharmaceutical preparation containing glutamine
SE8902544L (sv) * 1989-07-17 1991-01-18 Kabivitrum Ab Beredning foer naeringstillfoersel, samt saett foer dess framsaellning
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
SE9003844L (sv) * 1990-12-03 1992-06-04 Kabi Pharmacia Ab Naeringstillsats
IT1244880B (it) * 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
GB9121467D0 (en) * 1991-10-10 1991-11-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
ES2070076B1 (es) * 1993-04-20 1996-04-16 Cusi Lab Metodo para aumentar la estabilidad de las nanocapsulas durante su almacenamiento.
EP0738146B1 (de) * 1994-01-11 2003-05-02 N.V. Nutricia Verfahren zur behandlung von stoehrungen des menschlichen oder tierischen koerpers durch verabreichung von aminosaeuren
US6015798A (en) * 1995-10-10 2000-01-18 Colgate Palmolive Company Method for reducing the damaging effects of radiation therapy on animal skin and mucosa
EP0875155A1 (de) * 1997-05-01 1998-11-04 N.V. Nutricia Perioperatives Getränk
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
WO2004012662A2 (en) 2002-08-01 2004-02-12 Aesgen, Inc. Improved treatment of cancer with glutamine
EP1675480B1 (de) * 2003-10-16 2018-06-13 Nestec S.A. Nahrhafte zusammensetzung gegen die nebenwirkungen von chemotherapie oder strahlentherapie
EP1913943B1 (de) 2005-06-27 2011-09-21 Kyowa Hakko Bio Co., Ltd. Prophylaktische oder therapeutische zusammensetzung gegen hämoglobinurie oder myoglobinurie
NZ607189A (en) 2010-09-24 2015-04-24 Univ Florida Materials and methods for improving gastrointestinal function
US10350185B2 (en) 2013-03-11 2019-07-16 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1909591A (en) * 1928-06-20 1933-05-16 Novocol Chemical Mfg Co Inc Method of utilizing hypodermic medicaments, etc.
US2868693A (en) * 1956-07-16 1959-01-13 Shive William Peptic ulcer-treating compositions containing glutamine
US3217711A (en) * 1963-08-01 1965-11-16 Abbott Lab Valve apparatus for sequentially administering parenteral fluid from separate sources
US3195778A (en) * 1963-09-17 1965-07-20 Alta Engineering Company Storage and mixing cartridge
US3982534A (en) * 1975-01-10 1976-09-28 Buckman Thomas P Intravenous administration system
US4200095A (en) * 1977-08-15 1980-04-29 Millipore Corporation Arrangement for intravenous administration or the like
US4265240A (en) * 1979-04-16 1981-05-05 Imed Corporation Apparatus for providing a controlled introduction of intravenous fluid to a patient
US4334535A (en) * 1980-08-12 1982-06-15 Cutter Laboratories, Inc. Conduit device for rapid priming and flow of liquid
SE8101247L (sv) * 1981-02-26 1982-08-27 Haessle Ab Lekemedelsadministrationsanordning
US4396383A (en) * 1981-11-09 1983-08-02 Baxter Travenol Laboratories, Inc. Multiple chamber solution container including positive test for homogenous mixture
DE3206784C2 (de) * 1982-02-25 1985-05-09 Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen Glutaminhaltige Zubereitungen für orale oder intravenöse Applikation
JPS5927822A (ja) * 1982-08-05 1984-02-14 Kotobuki Seiyaku Kk 医療用組成物及びこの組成物を有効成分とする抗炎症抗潰瘍用剤

Also Published As

Publication number Publication date
AU6337886A (en) 1987-04-07
JPH0794389B2 (ja) 1995-10-11
DK241287D0 (da) 1987-05-12
DK241287A (da) 1987-07-10
JPS63501214A (ja) 1988-05-12
WO1987001589A1 (en) 1987-03-26
AU599335B2 (en) 1990-07-19
EP0238553B1 (de) 1997-05-07
EP0238553A4 (de) 1990-03-08
DE3650620D1 (de) 1997-06-12
EP0238553A1 (de) 1987-09-30
DK175711B1 (da) 2005-01-31
CA1285491C (en) 1991-07-02
ATE152621T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
DE3650620D1 (de) Behandlungsverfahren kataboler dysfunktion
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DK90888D0 (da) Maaleapparat til vaevsmetabolisme
DE3587741T2 (de) Behandlung von Hautkrankheiten.
DK71387A (da) Terapeutisk middel til behandling af psoriasis
DK586387A (da) Piperidinderivater til behandling af smertetilstande
DE3584560D1 (de) Arzneimittelzusammensetzung geeignet zur behandlung oder prophylaxe von herzstoerungen.
FR2585572B3 (fr) Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
DK472688D0 (da) Anvendelse af bezafibrat til behandling af diabetes
GR3006674T3 (de)
ATE149840T1 (de) Behandlung von leberkrebs
ATE22659T1 (de) Verfahren zur behandlung der azyklie bei schafen oder rindern.
EA199800535A1 (ru) Способ лечения боли
DE3373978D1 (en) Composition for the care or treatment of the human skin
GB2012163A (en) Composition for treating diarrhoea
DE3586197D1 (de) Verfahren zur reinigung sowie pasteurisierung von urokinase.
IE811612L (en) Thiazoles
GB1538932A (en) Therapeutic method of treating mink infection and bovine mastitis by pseudomonas aeruginosa
DE3674997D1 (de) Holzbehandlungszusammensetzung.
DE3680140D1 (de) Behandlung von parasiterkrankungen.
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
FR2574301B1 (fr) Appareil de traitement therapeutique par application d'un faisceau laser
PT86794A (pt) Process for the preparation of compositions for the treatment of wood and processes of treating wood

Legal Events

Date Code Title Description
8363 Opposition against the patent